Wedbush Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)

Research analysts at Wedbush started coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a report issued on Friday. The brokerage set an “outperform” rating and a $30.00 price target on the stock. Wedbush’s price target points to a potential upside of 51.07% from the stock’s previous close.

A number of other analysts have also weighed in on the stock. UBS Group assumed coverage on shares of First Tracks Biotherapeutics in a report on Tuesday. They issued a “buy” rating and a $45.00 price target for the company. JPMorgan Chase & Co. initiated coverage on First Tracks Biotherapeutics in a research note on Thursday. They set an “overweight” rating and a $31.00 price objective for the company. Leerink Partners started coverage on First Tracks Biotherapeutics in a report on Friday. They issued an “outperform” rating and a $46.00 price objective for the company. Finally, Barclays started coverage on First Tracks Biotherapeutics in a report on Wednesday. They set an “overweight” rating and a $40.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $38.40.

First Tracks Biotherapeutics Trading Up 5.2%

Shares of NASDAQ TRAX opened at $19.86 on Friday. First Tracks Biotherapeutics has a 52 week low of $14.79 and a 52 week high of $26.80.